• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Assertio Holdings Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    10/30/25 4:46:02 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASRT alert in real time by email
    false 0001808665 0001808665 2025-10-27 2025-10-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported)

    October 27, 2025

     

     

     

    ASSERTIO HOLDINGS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-39294   85-0598378
    (State or other jurisdiction of
    incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

     

    100 South Saunders Rd., Suite 300,

    Lake Forest, IL 60045

    (Address of principal executive offices, including zip code)

     

    (224) 419-7106

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Securities registered pursuant to Section 12(b) of the Act:

     

      Title of each class:   Trading Symbol(s):   Name of each exchange on which registered:  
      Common Stock, $0.0001 par value   ASRT   The Nasdaq Stock Market LLC  

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company  ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    Departure of Chief Executive Officer

     

    Effective as of October 27, 2025, Brendan O’Grady, Chief Executive Officer and a director of Assertio Holdings, Inc. (the “Company”) separated from service as Chief Executive Officer of the Company. Mr. O’ Grady’s separation constitutes an “Other Involuntary Termination,” as defined in the Management Continuity Agreement between Mr. O’Grady and the Company, a form of which was filed as Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q filed on August 7, 2024. As such, contingent upon Mr. O’Grady’s execution and non-revocation of a waiver and release in substantially the form included with the Management Continuity Agreement, Mr. O’Grady will be entitled to the severance compensation and benefits provided for in the Management Continuity Agreement in connection with an “Other Involuntary Termination.”

     

    Appointment of Chief Executive Officer

     

    Effective upon Mr. O’Grady’s separation, the Board of Directors of the Company (the “Board”) appointed Mark Reisenauer, currently a member of the Board, to serve as the Company’s Chief Executive Officer. Mr. Reisenauer’s biographical information is described in the Company’s Definitive Proxy Statement on Schedule 14A filed on April 8, 2025. Mr. Reisenauer will continue to serve as a member of the Board.

     

    On October 27, 2025, the Company entered into an offer letter with Mr. Reisenauer in connection with his service as the Chief Executive Officer (the “Offer Letter”). The Offer Letter provides that Mr. Reisenauer will receive a base salary at a rate of $800,000 per annum, with an annual target cash bonus opportunity of 85% of his base salary, except that he is not eligible for a cash bonus for the remainder of 2025. Mr. Reisenauer will also receive initial grants of (i) a stock option award (the “Option”) to acquire 1,000,000 shares of Company common stock and (ii) an award of 500,000 restricted stock units (the “RSUs”), in each case, pursuant to the Company’s Amended and Restated 2014 Omnibus Incentive Plan (as amended, the “Plan”), with one-third of each grant vesting each year over the three-year period following the grant date. Mr. Reisenauer will also be eligible to receive annual equity-based awards pursuant to the Plan.

     

    Mr. Reisenauer also entered into a Management Continuity Agreement (the “MCA”) with the Company. Pursuant to the terms of the Reisenauer MCA, upon Mr. Reisenauer’s termination other than for Cause, death or Disability, or Mr. Reisenauer’s voluntary termination for Good Reason (each as defined in the Reisenauer MCA) within the period beginning ninety days prior to a Change in Control (as defined in the Reisenauer MCA) and ending twenty-four months following a Change in Control (the “Change in Control Period”), subject to Mr. Reisenauer’s execution and non-revocation of a release of claims in favor of the Company and continued compliance with certain restrictive covenants, Mr. Reisenauer will be entitled to (i) a lump sum cash payment in an amount equal to two times the higher of (1) the base salary which Mr. Reisenauer was receiving immediately prior to the Change in Control or (2) the base salary which Mr. Reisenauer was receiving immediately prior to his termination of employment, payable on the 60th day following Mr. Reisenauer’s termination of employment or, if his termination of employment is prior to the Change in Control, on the date of the Change in Control; (ii) a lump sum cash payment in an amount equal to two times Mr. Reisenauer’s target annual bonus, payable on the 60th day following Mr. Reisenauer’s termination of employment or, if his termination of employment is prior to the Change in Control, on the date of the Change in Control; (iii) payment of the full cost of the health insurance benefits provided to Mr. Reisenauer and his spouse and dependents through the earlier of the end of the 24 month period following the date of termination or the date upon which Mr. Reisenauer is no longer eligible for such COBRA or other benefits under applicable law; (iv) payment of any earned but unpaid annual bonus for the year immediately preceding the year of termination, to be paid at the time the Company pays bonuses with respect to such year to its executives generally; (v) up to three consecutive months of outplacement services, not to exceed $5,000 per month and (vi) 100% of Mr. Reisenauer’s unvested option shares, restricted stock, restricted stock units, other equity-based awards and other long-term incentive awards will become immediately vested, provided that any performance-based awards will be calculated as set forth in the applicable award agreement or, if not specified therein, based on achieving the target level of performance. Notwithstanding the foregoing, in the event that a termination as described in this paragraph occurs prior to the date of the Change in Control, then if any of Mr. Reisenauer’s unvested option shares, restricted stock, restricted stock units, other equity-based awards and other long-term incentive awards are forfeited as the result of such termination of employment, Mr. Reisenauer will be entitled to receive a lump sum cash payment equal to the value of all such awards that were forfeited as the result of such termination of employment.

     

     

     

     

    In addition, pursuant to the terms of the Reisenauer MCA, upon Mr. Reisenauer’s termination other than for Cause, death or Disability or due to a voluntary termination for Good Reason that occurs outside of the Change in Control Period, subject to Mr. Reisenauer’s execution and non-revocation of a release of claims in favor of the Company and continued compliance with certain restrictive covenants, Mr. Reisenauer will be entitled to receive severance benefits as follows: (i) continuation of his base salary in effect immediately prior to his termination for 18 months after the effective date of the termination, payable in accordance with the Company’s standard payroll practices; (ii) payment of the full cost of the health insurance benefits provided to Mr. Reisenauer and Mr. Reisenauer’s spouse and dependents, as applicable, immediately prior to the termination of employment pursuant to the terms of COBRA or other applicable law through the earlier of the end of the 18 month period following the date of termination or the date upon which Mr. Reisenauer is no longer eligible for such COBRA or other benefits under applicable law; (iii) payment of any earned but unpaid annual bonus for the year immediately preceding the year of termination, to be paid at the time the Company pays bonuses with respect to such year to its executives generally; and (iv) up to three consecutive months of outplacement services, not to exceed $5,000 per month.

     

    The foregoing descriptions of the Offer Letter and the Reisenauer MCA do not purport to be complete and are qualified in their entirety by reference to the full text, which will be filed as exhibits to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

     

    In connection with his appointment as Chief Executive Officer, Mr. Reisenauer continues to have rights under his Indemnification Agreement for Directors and Officers, which he entered into upon joining the Board effective January 2, 2025, a form of which has been filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K12B filed with the Securities and Exchange Commission on May 19, 2020.

     

    There are no arrangements or understandings between Mr. Reisenauer and any other person pursuant to which he was selected as an officer or director of the Company. There are no family relationships between Mr. Reisenauer and any of the executive officers or directors of the Company. There is no information that is required to be disclosed with respect to Mr. Reisenauer pursuant to Item 404(a) of Regulation S-K.

     

     

     

     

    Item 7.01 Regulation FD Disclosure

     

    On October 28, 2025, the Company issued a press release announcing Mr. Reisenauer’s appointment. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

     

    The information in this Item 7.01, including Exhibit 99.1 attached hereto, is furnished pursuant to Item 7.01 of this Current Report on Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d)Exhibits

     

    99.1Press Release, dated October 28, 2025
      
    104Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: October 30, 2025

     

      ASSERTIO HOLDINGS, INC.
       
      /s/ Mark Reisenauer
      Mark Reisenauer
      Chief Executive Officer

     

     

     

    Get the next $ASRT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASRT

    DatePrice TargetRatingAnalyst
    7/26/2024$3.00Buy
    Maxim Group
    7/3/2024$4.00Buy
    H.C. Wainwright
    11/7/2022$7.00Buy
    Lake Street
    More analyst ratings

    $ASRT
    SEC Filings

    View All

    Assertio Holdings Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Assertio Holdings, Inc. (0001808665) (Filer)

    10/30/25 4:46:02 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assertio Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - Assertio Holdings, Inc. (0001808665) (Filer)

    10/10/25 4:50:32 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Assertio Holdings Inc.

    10-Q - Assertio Holdings, Inc. (0001808665) (Filer)

    8/11/25 4:10:58 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mason Heather L bought $60,000 worth of shares (75,000 units at $0.80), increasing direct ownership by 35% to 287,650 units (SEC Form 4)

    4 - Assertio Holdings, Inc. (0001808665) (Issuer)

    11/19/24 9:02:18 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO O'Grady Brendan P. bought $9,950 worth of shares (11,706 units at $0.85) (SEC Form 4)

    4 - Assertio Holdings, Inc. (0001808665) (Issuer)

    11/15/24 2:43:25 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Vacirca Jeff L bought $11,100 worth of shares (10,000 units at $1.11), increasing direct ownership by 7% to 151,159 units (SEC Form 4)

    4 - Assertio Holdings, Inc. (0001808665) (Issuer)

    6/12/24 6:00:09 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO O'Grady Brendan P. converted options into 166,665 shares and covered exercise/tax liability with 49,416 shares, increasing direct ownership by 1,002% to 128,955 units (SEC Form 4)

    4 - Assertio Holdings, Inc. (0001808665) (Issuer)

    6/3/25 6:00:13 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, General Counsel Schlessinger Sam converted options into 38,017 shares and covered exercise/tax liability with 14,958 shares, increasing direct ownership by 15% to 176,948 units (SEC Form 4)

    4 - Assertio Holdings, Inc. (0001808665) (Issuer)

    5/14/25 6:03:08 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Schwichtenberg Paul converted options into 38,017 shares and covered exercise/tax liability with 16,840 shares, increasing direct ownership by 14% to 167,522 units (SEC Form 4)

    4 - Assertio Holdings, Inc. (0001808665) (Issuer)

    5/14/25 6:01:08 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Assertio Holdings Inc.

    SC 13G/A - Assertio Holdings, Inc. (0001808665) (Subject)

    11/14/24 3:52:50 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Assertio Holdings Inc.

    SC 13G/A - Assertio Holdings, Inc. (0001808665) (Subject)

    11/12/24 1:34:28 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Assertio Holdings Inc.

    SC 13G/A - Assertio Holdings, Inc. (0001808665) (Subject)

    11/4/24 11:29:13 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Assertio Holdings Inc. on Jun 6

    Recent insider transactions at Assertio Holdings Inc. have brought attention to the company's stock activity. On June 6, 2024, Mason Heather L purchased $24,250 worth of shares, acquiring 25,000 units at $0.97 per share. This transaction increased Mason Heather L's direct ownership by 13% to 212,650 units, as reported in the SEC Form 4. Several other notable insider transactions have taken place at Assertio Holdings Inc. leading up to this purchase. Patel Ajay, Schwichtenberg Paul, and Schlessinger Sam all converted options into shares and covered exercise/tax liability by utilizing their shares. These transactions resulted in ownership increases of 16%, 20%, and 21%, respectively. Addition

    6/10/24 1:20:50 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Assertio Therapeutics with a new price target

    Maxim Group initiated coverage of Assertio Therapeutics with a rating of Buy and set a new price target of $3.00

    7/26/24 7:49:44 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Assertio Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Assertio Therapeutics with a rating of Buy and set a new price target of $4.00

    7/3/24 7:25:55 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lake Street initiated coverage on Assertio Therapeutics with a new price target

    Lake Street initiated coverage of Assertio Therapeutics with a rating of Buy and set a new price target of $7.00

    11/7/22 9:24:08 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Assertio Announces Leadership Transition

    Appoints Industry Veteran and Current Director Mark L. Reisenauer as CEO, Effective Immediately Company Will Report Third Quarter Results on November 10, 2025 and Expects to Update Guidance Within the Current Range at That Time LAKE FOREST, Ill., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), today announced that its Board of Directors (the "Board") has appointed director Mark L. Reisenauer as the Company's Chief Executive Officer ("CEO"), effective immediately. As part of this transition, current CEO Brendan P. O'Grady will be departing the Company. Heather L. Mason, Chair of the Board of Directors, stated, "After significant del

    10/28/25 9:15:00 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN® (clobazam) Oral Film, CIV

    New data show how Sympazan is being used in daily clinical practice to treat patients with Lennox-Gastaut Syndrome (LGS), a severe form of childhood-onset epilepsyStudy addresses lack of awareness and real-world data with oral film formulation of clobazamNew data presented during poster session at 150th Annual Meeting of the American Neurological AssociationSYMPAZAN is the only FDA-approved oral film formulation of clobazam for adjunctive treatment of seizures associated with LGS in patients two years of age or older BALTIMORE, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial

    9/15/25 9:00:00 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assertio to Present New Data from Real-World Evidence Study of SYMPAZAN® at upcoming 150th Annual Meeting of the American Neurological Association

    Poster presentation will feature new data for SYMPAZAN, the only FDA-approved oral film formulation of clobazam for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients two years of age or olderAbstract is now available on ANA2025 website LAKE FOREST, Ill., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients' needs, today announced that the company will present new data for SYMPAZAN (clobazam) Oral Film in a poster presentation at the 150th Annual Meeting of the American Neurolo

    9/10/25 7:30:14 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    Leadership Updates

    Live Leadership Updates

    View All

    Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors

    LAKE FOREST, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced today that Mark Reisenauer has been appointed as an independent director to the Company's Board of Directors. Mr. Reisenauer will serve as a member of the Compensation Committee. "Mark is a highly accomplished commercial leader in complex, competitive therapeutic areas who also brings extensive oncology and hematology product experience to our board," said Heather Mason, Chair of Assertio. "His successful new product and indication launches have b

    12/17/24 8:30:00 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCO

    LAKE FOREST, Ill., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced today the creation of a new Transformation Office and the appointment of Paul Schwichtenberg as Chief Transformation Officer (CTO). Mr. Schwichtenberg currently serves as the company's Chief Commercial Officer and was previously CFO. "As CTO, Paul will be future looking, working closely with me, to identify synergies, innovative strategies, and new revenue streams to best position the company for future growth," said Brendan O'Grady, Chief Executi

    12/12/24 8:00:00 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

    CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer (CFO), effective December 19, 2024. Mr. Emany brings to Beam a breadth of global operational, commercial and financial experience with multinational public corporations and financial institutions. He most recently served as CFO and chief operating officer at Ironwood Pharmaceuticals, Inc. "Beam has built a strong financial position to advance our portfolio of genetic medicines, and Sravan has an exceptional background to lead our capital fo

    12/6/24 7:00:00 AM ET
    $ASRT
    $BEAM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ASRT
    Financials

    Live finance-specific insights

    View All

    Assertio Announces Leadership Transition

    Appoints Industry Veteran and Current Director Mark L. Reisenauer as CEO, Effective Immediately Company Will Report Third Quarter Results on November 10, 2025 and Expects to Update Guidance Within the Current Range at That Time LAKE FOREST, Ill., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), today announced that its Board of Directors (the "Board") has appointed director Mark L. Reisenauer as the Company's Chief Executive Officer ("CEO"), effective immediately. As part of this transition, current CEO Brendan P. O'Grady will be departing the Company. Heather L. Mason, Chair of the Board of Directors, stated, "After significant del

    10/28/25 9:15:00 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assertio Holdings, Inc. to Report Second Quarter 2025 Financial Results on August 11, 2025

    LAKE FOREST, Ill., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that it will release second quarter 2025 financial results on Monday, August 11, 2025, after the market close. Additionally, Assertio's management will host a live webcast conference call at 4:30 p.m. Eastern Time to discuss the financial results and provide business updates on the Company's 2025 strategic plans. To access the live webcast, conference call information, and other materials, please visit Assertio's investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcas

    8/5/25 8:30:00 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assertio Holdings, Inc. to Report First Quarter 2025 Financial Results on May 12, 2025

    LAKE FOREST, Ill., May 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that it will release first quarter 2025 financial results on Monday, May 12, 2025, after the market close. Additionally, Assertio's management will host a live webcast conference call at 4:30 p.m. Eastern Time to discuss the financial results and update the Company's 2025 strategic plans. To access the live webcast, conference call information, and other materials, please visit Assertio's investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcast to ensure adequate tim

    5/5/25 8:15:00 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care